the present invention relates to the connection, which selectively activates the \u0433\u043b\u044e\u043a\u043e\u043a\u0438\u043d\u0430\u0437\u0443 in the liver and, in particular, to become an agent for the treatment and warned and diabetes and reduced glucose tolerance, where the agent has low \u0433\u0438\u043f\u043e\u0433\u043b\u0438\u043a\u0435\u043c\u0438\u0447\u0435\u0441\u043a\u0438\u0439 risk.a compound represented by the formula (1), as shown below, or its salt, or \u0441\u043e\u043b\u044c\u0432\u0430\u0442 compounds or salts, where, in the formula (1) and means \u0442\u0438\u0430\u0437\u043e\u043b\u0438\u043b\u044c\u043d\u0443\u044e groo cycle polyurethane \u043f\u0438\u0440\u0438\u0434\u0438\u043b\u044c\u043d\u0443\u044e group \u043f\u0438\u0440\u0430\u0437\u0438\u043b\u044c\u043d\u0443\u044e group or \u043f\u0438\u0440\u0430\u0437\u043e\u043b\u0438\u043b\u044c\u043d\u0443\u044e group l is - (co) -, - (cs) - or (-) - and R\u043e\u0437\u043d\u0430\u0447\u0430\u0435\u0442 c - \u0430\u043b\u043a\u0438\u043b\u044c\u043d\u0443\u044e group, hmg - c - c - \u0430\u043b\u043a\u043e\u043a \u0430\u043b\u043a\u0438\u043b\u044c\u043d\u0443\u044e group strong team \u0430\u043c\u0438\u043d\u043e\u0433\u0440\u0443\u043f\u043f\u0443, c - \u0430\u043b\u043a\u0438\u043b\u0430\u043c\u0438\u043d\u043e\u0433\u0440\u0443\u043f\u043f\u0443,\u0433\u0438\u0434\u0440\u043e\u043a\u0441\u0438\u0430\u043c\u0438\u043d\u043e\u0433\u0440\u0443\u043f\u043f\u0443, n - c - \u0430\u043b\u043a\u0438\u043b\u043a\u0430\u0440\u0431\u0430\u043c\u043e\u0438\u043b\u044c\u043d\u0443\u044e group or a group of the following formula (2), as shown below, where the R\u043e\u0437\u043d\u0430\u0447\u0430\u0435\u0442 c - \u0430\u043b\u043a\u0438\u043b\u044c\u043d\u0443\u044e group and R\u043e\u0437\u043d\u0430\u0447\u0430\u0435\u0442 hydrogen atom, halogen atom, c - \u0430\u043b\u043a\u0438\u043b\u044c\u043d\u0443\u044e group c - \u0430\u043b\u043a\u043e\u043a\u0441\u0438\u043b\u044c\u043d\u0443\u044e grou
